LifeMD (LFMD) Preferred Stock Liabilities (2020 - 2023)

LifeMD has reported Preferred Stock Liabilities for 4 years, with the latest figure at $5.0 million in Q2 2023.

• For the quarter ending Q2 2023, Preferred Stock Liabilities rose 16.06% year-over-year to $5.0 million; the trailing twelve-month figure through Jun 2023 stood at $5.0 million (up 16.06% YoY), and the FY2022 full-year result was $4.6 million, up 11.07% from the prior year.
• Preferred Stock Liabilities for Q2 2023 stood at $5.0 million, up from $4.7 million in the prior quarter.
• The five-year high for Preferred Stock Liabilities was $5.0 million in Q2 2023, with the low at $3.7 million in Q4 2020.
• Historically, Preferred Stock Liabilities has averaged $4.2 million across 4 years, with a median of $4.2 million in 2022.
• The largest YoY upside for Preferred Stock Liabilities was 16.06% in 2023 against a maximum downside of 10.77% in 2023.
• LifeMD's Preferred Stock Liabilities stood at $3.7 million in 2020, then advanced by 12.45% to $4.1 million in 2021, then increased by 11.07% to $4.6 million in 2022, then rose by 10.23% to $5.0 million in 2023.
• The last three Preferred Stock Liabilities figures came in at $5.0 million (Q2 2023), $4.7 million (Q1 2023), and $4.6 million (Q4 2022), per Business Quant data.